[The differentiated treatment of patients with duodenal peptic ulcer].
There were 45 patients suffering from duodenal ulcer in the stage of exacerbation and 15 subjects who served as control. Radioimmunoassay and immunomorphological PAP methods were used to examine the blood PGI and gastrin levels, the number of gastroduodenal G and D cells, the characteristics of basal and stimulated acid production in gastric juice in the treatment with gastrozepin (22 persons) and ranisen (23 persons). Depending on the concentration of gastrin in the blood and the number of pyloric G cells, the patients were distributed into two groups: with hypergastrinemia and/or hyperplasia of G cells (48%) and with normogastrinemia and the normal number of these cells (52%). It has been shown that the continuous treatment with gastrozepin of the patients with hypergastrinemia and/or hyperplasia of pyloric G cells was followed by the normalization of blood gastrin concentration and of the number of pyloric G cells; on the contrary in the patients with normogastrinemia and the normal amount of these cells, the analogous characteristics remained unchanged. After the treatment with ranisan the patients with normogastrinemia and the normal amount of pyloric G cells manifested hypergastrinemia without any changes in the amount of G cells; meanwhile in the patients with hypergastrinemia and/or hyperplasia of G cells, the analogous characteristics were unchanged. In these groups patients, the rate and the times of the relapse occurrence were different throughout the whole year. The data obtained support the nonuniformity of duodenal ulcer.
Minushkin
O N
ON
Zverkov
I V
IV
D000328:Adult; D001706:Biopsy; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005744:Gastric Acid / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D010435:Pepsinogens / Q000097:blood; D010890:Pirenzepine / Q000627:therapeutic use; D011708:Pylorus / Q000473:pathology; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction
D005755:Gastrins; D010435:Pepsinogens; D010890:Pirenzepine; D011899:Ranitidine
Differentsirovannoe lechenie bol'nykh iazvennoĭ bolezn'iu dvenadtsatiperstnoĭ kishki.